Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.
Darolutamide, enzalutamide (Xtandi), and apalutamide (Erleada) have all demonstrated promising findings, signifying that therapies are moving forward in this space. It is exciting to see that patients now have a lot of options, Fleming says.
Similar to having several pairs of black shoes and choosing the right pair for the right occasion, Fleming says patients with prostate cancer will have different therapy options for different situations.
- Dr. Fleming Shares Encouraging Data With Antiandrogen Therapies in Prostate Cancer ( Download)
- Expert Discusses Toxicity Results in CARD Study ( Download)
- Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer ( Download)
- ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC ( Download)
- Dumbest in the Room with Dr. Mark T. Fleming - Genitourinary Oncologist ( Download)
- Xtandi40mg Anticancer ( Download)
- Palliative Care - Dr. Manish Agrawal ( Download)
- Best of ASCO 2019: Lung and Genitourinary Cancers - J. Weiss & T. Rose - 20190828 ( Download)
- 2/21/22 Hi-Risk/Recurrent/Advanced PCa Men & Caregiver ( Download)
- LIVE Panel of Experts and Breast Cancer Advocates ( Download)
- John Doyle Doesn't Read Studies ( Download)
